Dhaka Medical College Randomized Controlled Study Evidencing Efficacy of Ivermectin Published in Journal of International Medical Research

Dhaka Medical College Randomized Controlled Study Evidencing Efficacy of Ivermectin Published in Journal of International Medical Research

Back in late October 2020, TrialSite reported that Dhaka Medical College conducted a randomized controlled trial showcasing the safety and apparent efficacy of ivermectin as a treatment for COVID-19. The results then were uploaded on a preprint server but hadn’t been peer-reviewed or published. The findings of this study indicated a potential benefit of ivermectin and doxycycline for patients with mild to moderate SARS-CoV-2 infection. This study was picked up by the Journal of International Medical Research recently. Led by Professor Reaz Mahmud, Department of Neurology, Dhaka Medical College in Bangladesh, and colleagues, the team sought to test if ivermectin combined with doxycycline, known as “the people’s medicine” out of Bangladesh, could reduce the clinical recovery time in adults with COVID-19 infection. The results indicate benefits that at this point shouldn’t be ignored by the global healthcare community, including the World Health Organization (WHO).

The Study 

Registered on clincialtrials.gov (NCT04523831), the randomized, blinded, placebo-controlled trial in COVID-19 patients with mild-to-moderate symptoms were randomly assigned to treatment (200) and plac...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee